Study Design: Retrospective study. Purpose: To report the prevalence of patients with multidrug-resistant (MDR) tubercular spondylodiscitis and their outcomes. Additionally, to assess the role of Xpert MTB/RIF assay in early detection of MDR tuberculosis. Overview of Literature: MDR tuberculosis is increasing globally. The World Health Organization (WHO) has strongly recommended Xpert MTB/RIF assay for early detection of tuberculosis. Methods: From 2006 to 2015, a retrospective study was conducted on patients treated for MDR tuberculosis of the spine. Only patients whose diagnosis was confirmed using either culture and/or the Xpert MTB/RIF assay were included. Diagnostic method, treatment regimen, time taken to initiate second-line antituberculosis treatment (ATT), drug-related complications, and cost of medications were analyzed. All patients with MDR were treated according to the WHO recommendations for 2 years. The outcome parameters analyzed included clinical, biochemical, and radiological criteria to assess healing status. Results: From 2006 to 2015, a total of 730 patients were treated for tubercular spondylodiscitis. Of those, 36 had MDR tubercular spondylitis (prevalence, 4.9%), and three had extremely drug resistant tubercular spondylitis (prevalence, 0.4%). In this study, 30 patients, with a mean age of 29 years and a mean post-treatment follow-up of 24 months, were enrolled. The majority (77%) had secondary MDR, 17 (56%) underwent surgery, and 26 (87%) completed treatment for 2 years and were healed. Drug-related complications (33%) included ototoxicity, hypothyroidism, and hyperpigmentation of the skin. The average time taken for initiation of second line ATT for MDR patients with Xpert MTB/RIF assay as the diagnostic tool was 18 days, when compared to patients for whom the assay was not available which was 243 days. Conclusions: The prevalence of MDR tubercular spondylodiscitis was 4.9%. In total, 87% of patients were healed with adequate treatment. The sensitivity and specificity of the Xpert MTB/RIF assay to detect MDR was 100% and 92.3%, respectively.
Introduction
Multidrug-resistant tuberculosis (MDR-TB) is alarmingly on the rise, specially in developing countries. In 2016, the World Health Organization (WHO) had declared 30 countries as 'high MDR-TB burden' countries [1] . According to the 2017 WHO report [2] , 600,000 new cases of tuberculosis with resistance to rifampicin (RR-TB) were notified in 2016, of which 490,000 had MDR-TB. Almost half (47%) of these cases were from India, China, and the Russian Federation. Globally, an estimated 4.1% of new cases and 19% of previously treated cases in 2016 had MDR/RR-TB. The percentage of patients in India with either MDR-TB or RR-TB is estimated to be 2.8% among new TB cases and 12% among previously treated cases [2] .
Musculoskeletal tuberculosis often poses diagnostic challenges because of its chronic and indolent nature. The rise in the number of cases of MDR tubercular spondylodiscitis has resulted in the necessity for early diagnosis of this disease. In 2015, WHO recommended Xpert MTB/ RIF assay (Xpert; Cepheid, Sunnydale, CA, USA) [3] to detect extra pulmonary tuberculosis. However, to date, few studies reporting MDR tubercular spondylodiscitis have been published in English literature [4, 5] . This study was undertaken with the objectives to report the prevalence of MDR tubercular spondylodiscitis at our tertiary care center and the outcomes of patients treated with second-line antituberculosis treatment (ATT). Secondly, to assess the role of Xpert MTB/RIF assay in detecting RR-TB.
Materials and Methods
This was a retrospective study conducted from 2006 to 2015 (9 years) in our tertiary care center on all patients who were treated for multidrug-resistant tubercular spondylodiscitis. Only patients with proven MDR-TB (defined in Table 1 ) with either a positive culture and drug susceptibility test and/or a positive Xpert RIF/MTB assay were enrolled. Patients with other infective spondylodiscitis (pyogenic, fungal, etc.), those with inadequate follow-up, and those who did not provide consent for the study were excluded.
Parameters studied
Demographic profiles of the patients, including age, sex, and residence details, were collected. History of contact with tuberculosis, previous infection with tuberculosis, and prior treatment with anti-tuberculous chemotherapy (dosage and duration) was recorded. Severity of pain (assessed by Visual Analog Scale [6] ), deformity (measured using Konstam's method by Konstam and Blesovsky [7] ), neurological status of the patient (assessed using the American Spinal Injury Association [ASIA] Impairment Scale [8] ), and the ability to bear weight or sit comfortably were assessed. Blood parameters included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and liver function tests. Plain radiographs and magnetic resonance imaging (MRI) of the affected region were performed prior to and after completion of the treatment.
The indications for surgery included, substantial mechanical instability due to vertebral destruction [9] , neurological deficits (ASIA A, B, and C), and deformity >40°.
All patients were treated with five groups of second-line ATT for a period of 24 months according to drug susceptibility tests and WHO recommendations for pulmonary MDR tuberculosis [10, 11] . Drug-related complications and cost of medications were also assessed.
Patients were followed up every 2 months for first 6 months, followed by quarterly visits for the rest of the first year, and finally twice yearly until the completion of the therapy. Annual follow-ups occurred thereafter.
Outcome analyses included clinical, biochemical, and radiological criteria to assess the healing status. Clinical parameters included pain, healing of sinuses, and return to work, as per MacNab's criteria [12] . Serological markers included decrease in ESR and CRP levels. Radiological criteria for healing included the presence of remineralization and reappearance of bony trabeculae, sharpening of articular margin, sharpening of cortical margin, sclerosis of vertebral bodies and end plates, and the fusion of vertebral bodies as revealed by plain X-rays. MRI criteria for healing included: the complete absence of paravertebral collection, complete resolution of enhanced vertebral body, and fatty replacement of marrow [4] . Thyroid function tests, audiometry, liver and renal function tests were performed to consider possible drug-related adverse effects.
Results
During the 9-year study period, a total of 730 patients were treated for tubercular spondylodiscitis at our tertiary care center, of which 36 had MDR tubercular spondylodiscitis. One patient died because of septicemia and five were lost during follow-up. As a result, 30 patients were enrolled in the study (Fig. 1 ). The mean age of patients was 29 years (range, 5-56 years) and mean post-treatment follow-up was 24 months. The cohort had 14 men and 16 women, and six of them were children. Geographically, 63% were from the eastern states of India and 26% were from the northeastern states of India. The majority (77%) of the patients had history of being treated with first-line ATTs for an average period of 6-7 months. Radiologically, 23 patients (76.7%) had para-discal involvement and seven patients (23.3%) had vertebral involvement. Multicentric vertebral involvement was seen in seven patients (23%). There was no preponderance among affected spinal levels. The dorsal, lumbar, or dorso-lumbar vertebrae were affected without a significant pattern.
Only 17 patients (56%) underwent surgery, whereas the remainder had biopsies to confirm the diagnosis. Of the 17 patients, 15 underwent surgical decompression of the cord using the 'extended posterior circumferential decompression (EPCD)' approach [13] . Among the patients Table 1 . Definitions relating to TB and resistance patterns
Definitions

Mono-resistance
Resistance to one first-line anti-TB drug only
Poly resistance Resistance to more than one first-line anti-TB drug (other than both isoniazid and rifampicin)
Multidrug resistance Resistance to at least both Isoniazid and rifampicin
Extensively drug resistance Re sistance to any fluoroquinolone and to at least one of the three second-line injectable drugs (capreomycin, kanamycin, and amikacin), in addition to multidrug resistance
Rifampicin resistance
Re sistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, whether mono-resistance, multidrug resistance, poly-drug resistance or extensive drug resistance Primary resistance Pa tients may be erroneously labelled as having primary resistance if they do not disclose previous treatment for TB. Remained the same and he is on bladder and bowel rehabilitation. who had surgery, 60% had neurological deficits, 60% had significant spinal deformity, and all of them presented with mechanical instability. In total, 26 patients (87%) completed 2 years of therapy and were found to have both clinical and radiological evidence of healing. The remaining four patients are presently on MDR treatment. The results of treated patients have been formulated in Table 2 .
Role of Xpert MTB/RIF assay in multidrug-resistant
The Xpert MTB/RIF assay is a polymerized chain reaction test to diagnose tubercular spondylodiscitis and RR. In 2012, it was made available at our center. Therefore, of the 30 patients in the study group, only 13 had the diagnosis confirmed using the Xpert MTB/RIF assay. Only patients treated from January 2012 were included in the analysis to detect the role of Xpert MTB/RIF assay to diagnosis Rifampicin resistance. In total, 112 patients were culture positive for tuberculosis using Lowenstein-Jensen solid media for tubercular bacilli. Out of the 112 patients, 99 had culture sensitive tuberculosis, and 13 had MDR-TB. Among the 13 patients with MDR-TB, 12 were revealed to have RR by the Xpert MTB/RIF assay. Sensitivity and specificity of the Xpert MTB/RIF assay to detect RR was determined to be 100% and 92.3%, respectively (Table 3) .
Initiation of second-line antituberculosis treatment
The time duration between their presentation to the hospital and the initiation of second-line ATT for patients with MDR-TB was 18 days on average when the Xpert MTB/RIF assay was used as the initial diagnostic tool. In patients without an Xpert MTB/RIF assay diagnosis, the time taken to initiate second-line ATT was 243 days since presentation.
Drug-related complications
Drug-related complications occurred in 33.3% (10 of 30) patients, with a total of 14 recorded events. The most common complications were hypothyroidism due to ethionamide (36%) and aminoglycoside induced ototoxicity (28%). Other toxicities included linezolid-induced peripheral neuropathy and optic neuritis, clofazimineinduced hyperpigmentation, and para-amino salicylic acid-induced severe gastritis. Of 30 patients, 10% had to discontinue medications because of adverse effects.
Cost of second-line antituberculosis treatment
The cost of medications for patients treated with firstline chemotherapy was on an average Rs. 3,648 ($53) for a period of 9 months. The cost of patients treated with 2nd line chemotherapy for MDR for a period of 2 years was on an average Rs. 2,57,000 ($ 3775).
Illustration 1
A 50-year-old man presented with low backache for a period of 6 months. There was no history of contact with tuberculosis. Clinically, there was no neurological deficit. Plain radiography revealed sacralization of the L5 vertebra and erosion at the upper end plate of the L3 vertebra ( Fig. 2A) . The L2/3 disk space was reduced. MRI revealed an intraosseous abscess at the L2/3 vertebrae with associated involvement of the L1/2 and L2/3 disc spaces (Fig.  2B) . Ultrasound guided aspiration of the psoas abscess revealed MDR tuberculosis. The patient was initiated with second-line ATT, and following a 2-year follow-up, plain radiography revealed sclerosis of the involved vertebrae with a positive 'sentinel sign'-bony fusion was observed at the L2/3 level (Fig. 2C ).
Illustration 2
A 35-year-old woman presented with complaints of pain in the mid back and weakness in the lower limbs for a period of 1 month. One year prior, she had been treated with ATT for pulmonary tuberculosis. Clinically, she had a gibbus deformity of the mid back extending over the spinous processes from D10 to L1. Furthermore, she had an ASIA B paraplegia with grade 0 motor power and decreased peri-anal sensation. Plain radiography revealed near complete destruction of the D11 and 12 vertebrae with a 69.9° kyphosis (Fig. 3A) . A T2-weighted sagittal MRI revealed complete destruction of the D11 and 12 vertebrae with additional erosion observed in the D10 vertebra (Fig. 3B ). An intraosseous abscess extended into the epidural space leading to significant impingement of the spinal cord. The patient underwent circumferential decompression of the cord via the 'EPCD' approach. After thorough debridement and decompression of the cord, the anterior defect was reconstructed with a titanium mesh cage filled with morselized autogenous cancellous bone graft. Intraoperative samples revealed MDR tuberculosis. The patient was initiated on second-line ATT according to drug sensitivity testing. She gradually improved to ASIA E over a period of 4-6 months. Fig. 3C and D show the postoperative Xray and MRI, respectively, with 4.9° kyphosis and almost complete resolution of the abscess.
Discussion
Treatment of MDR tuberculosis remains a challenge, as the number of cases are on the rise, particularly in developing countries. There are multiple causes for developing resistance to tuberculosis, and some papers have described MDR-TB as a 'man-made' disease [4, 5] . The risk factors for developing resistance have been reported as young age (25-44 years), female gender, patients with human immunodeficiency virus infection, previous treatment for tuberculosis, or are in contact with a person with MDR-TB [14] . In our study, the patients were young, with a mean age of 29 years, and although there was no sex predilection, 77% had been previously treated for tuberculosis.
WHO recommends the use of the Xpert MTB/RIF assay to detect extrapulmonary tuberculosis [15] and as a replacement test for other non-respiratory specimens. However, the latter is a conditional recommendation based on low-quality evidence [2] . The advantages of using the Xpert MTB/RIF assay are early detection of tuberculosis (<2 hours) [16] and its ability to detect RR. In this study, only 43% (13 of 30) of patients were diagnosed with Xpert assay because of its availability. Nevertheless, the sensitivity and specificity of the Xpert MTB/RIF assay to detect RR in our study was 100% and 92.3%, respectively. These findings were similar to those obtained by Held et al. [17] .
Importantly, a significant reduction in the time interval between initial presentation at the hospital and diagno- A B C D sis of disease was noted. For patients diagnosed with the Xpert MTB/RIF assay, therapy was initiated almost 7 months (225 days) earlier than those patients in whom the assay was not done. Early detection of MDR-TB aids in prompt initiation of the appropriate ATT, which in turn significantly reduces devastating neurological complications and permanent disabilities due to MDR tubercular spondylodiscitis [18] . Early detection also helps prevent the gradual transformation of drug-susceptible tuberculosis to a drug-resistant epidemic state, particularly in 'high MDR-TB burden' countries such as India. WHO has outlined specific recommendations for the treatment of drug resistant pulmonary tuberculosis. However, until recently, there were no particular guidelines for the treatment of drug resistant 'extrapulmonary' tuberculosis. In 2014, WHO recommended that patients with drug resistant 'extrapulmonary' tuberculosis to be treated using the same protocol as that of drug resistant pulmonary tuberculosis [19] . All patients in this study were treated according to the WHO protocol for drug resistant pulmonary tuberculosis after drug susceptibility testing. In total, 87% (26 of 30) of patients completed a 2-year treatment plan with the appropriate second-line ATT and were cured of the disease.
Drug toxicity was encountered in approximately one third of the patients. Managing the adverse effects of the drugs used to treat MDR-TB can be challenging. However, failure to address these problems can result in poor adherence and an opportunity for tuberculosis to develop further resistance. Adverse effects in a similar cohort of MDR-TB patients included ototoxicity (41.8%), psychiatric disorders (21.3%), gastrointestinal disturbance (14.0%), arthralgia (11.4%), epileptic seizures (9.9%), hepatitis (4.5%), and dermatological effects (4.5%) [20] . In contrast, patients in this cohort primarily developed hypothyroidism due to ethionamide and ototoxicity due to aminoglycoside therapy. Central nervous system toxicity was not encountered in our study.
Close monitoring of patients is necessary to ensure that adverse effects of second-line drugs are promptly recognized. Although the patient can reliably report most adverse effects, it remains important to have physicians trained to screen patients regularly for the symptoms of common adverse effects.
The cost per patient analysis of MDR patients revealed 70 times increase when compared to that of conventional 1st line anti-tuberculous treatment. This finding is comparable to that in the 2015 WHO report [21] . Cost analysis excluded the cost of surgery, surgical implants, hospital consultations, investigations, drug-related complications and patients travel expenses.
Conclusions
Prevalence of MDR tubercular spondylodiscitis was 4.9%. The sensitivity and specificity of the Xpert assay for rifampicin resistance was 100% and 92.3%, respectively. The average time to initiation of second-line ATT for MDR patients was decreased by 7 months when the Xpert MTB/ RIF assay was used as a diagnostic tool.
